The combination of MEK inhibitors with PD-1 inhibitors and CTLA-4 inhibitors has synergically promoted durable tumor regression and longevity of tumor-infiltrating CD8+ T cells to provide additional efficacy in preclinical mouse models [14, 15]. This evidence concerns the gene MAP2K7 and neoplasm.